Trump's tariff threat on generics: Why it matters for Indian pharma firms, Pg15

Key Highlights:

• US President Donald Trump announced a threat to impose 100% tariffs on generic drugs after two years, escalating to 200% thereafter, to promote "reshoring" of pharmaceutical production to the US.
• The US is India’s largest market for pharmaceutical exports, accounting for nearly 40% of India's total pharma exports, with 90% of these being generics.
• Indian pharmaceutical companies are increasing outbound investments in the US, with Sun Pharmaceutical Industries acquiring Organon & Co. for $11.8 billion.
• Outbound investment from India to the US in the pharma sector reached $4.08 billion in FY26, the highest in four years.

US tariff on generic drugs.jpg

Detailed Insights:

• Trump's tariff threats are largely seen by experts as a strategy to encourage global pharma giants to boost investments in the US rather than to actually implement tariffs.
• Previous un-implemented tariff threats included 100% on specified branded medicines under Section 232 of the Trade Expansion Act of 1962 and on imported branded and patented medicines.
• Several leading Indian drug makers, including Sun Pharma, Zydus Lifesciences, Lupin, Aurobindo Pharma, Cipla, and Dr Reddy’s Laboratories, already operate US-based manufacturing facilities.
• The Gulf of Oman is a critical maritime corridor for global oil trade.
• The US imported $213 billion worth of pharmaceutical products in 2025, with $94.1 billion being finished medicines, a category that includes generics.
• Cipla is expanding production at its plants in Massachusetts and New York, while Dr Reddy’s Laboratories is open to increasing US manufacturing if commercially viable.

Key Concepts Involved:

• Tariffs: Taxes imposed by a government on imported goods and services.
• Generic Drugs: Pharmaceutical products that are bioequivalent to a brand-name drug but are typically sold at a lower price.
• Reshoring: The process of returning the manufacturing of goods to the company's country of origin.
• Section 232 of the Trade Expansion Act of 1962: A US law allowing the President to impose tariffs on imports if they are deemed a threat to national security.